Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

What condition was this medication prescribed to treat?

What Type of Incident Did You have (Heart Attack, Stroke, etc)

Incident Date 

How Long Were You On Vytorin Before The Incident Occured

If other, please explain: 

Did insurance cover your medication?

What was your total out of pocket expense?

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Vytorin Named in Another Lawsuit

Jun 9, 2009 | Parker Waichman LLP Vytorin, the controversial cholesterol-lowering drug, has been named in yet another lawsuit.  According to, the Pennsylvania Employees Benefit Trust Fund (PEBTF) has filed suit against Merck & Co. and Schering-Plough, alleging that the companies charged too much for both Vytorin, and Zetia, another cholesterol drug, which is also a component of Vytorin.

Vytorin, a combination of the statin Zocor (simvastatin) and  Zetia, has been under the microscope since the ENHANCE study, which found the drug was no better than a cheaper, generic statin in preventing clogged arteries, was released in January 2008. Merck and Schering-Plough delayed releasing ENHANCE for more than a year – the trial was actually completed in 2006.   

The ENHANCE controversy spawned well over 100 lawsuits that allege Merck and Schering-Plough were fraudulent by withholding the study results for so long. Investigations into the ENHANCE debacle and the marketing of  Vytorin are also being conducted in Congress, by the U.S. Justice Department and several state attorneys general.

According to Bloomberg,  the PEBTF -  an insurance fund for active and retired state employees  - alleges  that Merck and Schering-Plough's misleading claims about Vytorin and Zetia caused consumers to pay too much for the drugs.  The lawsuit claims that the companies "suppressed" the results of ENHANCE and  used false and deceptive marketing techniques claiming Vytorin was more effective than and just as safe as the much cheaper generic cholesterol  drugs.

"For more than a year, Defendants have known (but have failed to make public) that their own study shows that Zetia does not reduce the fatty arterial plaques that can cause heart attack and stroke," the complaint reads.  "Despite this knowledge, Defendants have touted the Zetia 'difference,' claiming that it would reduce arterial plaque. Defendants' failure to reveal that Zetia does not in fact reduce arterial plaque constitutes a deceptive practice employed by Defendants to cause physicians to prescribe, and patients to take, Vytorin or Zetia instead of the much less expensive and equally effective generic drug simvastatin."

The PEBTF lawsuit was filed  June 5 in Philadelphia federal court, Bloomberg said.   The PEBTF is seeking  to recoup more than $9 million spent on the two drugs since October 2002.

Other articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo